Interviews with leading Life Sciences companies: Cellestia Biotech AG

Created by two scientists at the École Politechnique Fédérale de Lausanne (EPFL) in 2014 and joined by experienced drug development and business professionals in 2015, Cellestia Biotech AG is developing oral medication along with companion diagnostics for Notch dependent hematological malignancies and solid tumors. Venture Valuation (VV) interviewed the CEO, Dr. Michael Bauer in Basel, … Continue reading Interviews with leading Life Sciences companies: Cellestia Biotech AG

Read more